In summary, the results of this study provide insights into the costs of IRD patients treated with TNF inhibitors in Switzerland and are the first real-world cost estimates for the entire spectrum of rheumatic diseases for which TNF inhibitors are approved to treat. This evidence concerns the gene TNF and rheumatic disorder.